On February 24, 2021, YS Biopharma announced the closing of over $130 million in its Series B financing. This round of investment was jointly led by Oceanpine and OrbiMed. Following the Series B financing, the company's institutional investors include Oceanpine, OrbiMed, Eight Roads, F-Prime, 3W Capital, Hillhouse Capital, Adjuvant Capital, Msa Capital, AIHC, Epiphron Capital, Superstring Capital, and Haitong International.

CEC Capital Group served as the exclusive financial advisor for YS Biopharma in this transaction.

The funds from this round of financing will support the construction of the company's research and development center, facilitate multiple vaccine products' multi-center clinical trials in China and internationally, and accelerate the establishment of biological vaccine production bases in China and Singapore. This will expedite the commercialization of products.